HLUYY News and Press, H Lundbeck A/S S/Adr

The success of a pivotal study of Rexulti in Alzheimer's-associated agitation brings an underserved market worth $1 billion or more per year into reach. First quarter results saw better-than-expected sales growth and margins, but the launch of Vyepti continues to underwhelm. In ad...

Denmark-based H. Lundbeck (OTCPK:HLUYY) (OTC:HLUKF) and Japan's Otsuka (OTCPK:OTSKF) (OTCPK:OTSKY) said their medicine brexpiprazole helped reduce agitation, compared to placebo, in patients with Alzheimer's dementia in a phase 3 trial. The companies aid based on the outcome are planning...

Lundbeck has been beating Street operating earnings expectations, but the core growth-driving drugs have had more mixed performances, with marketing efforts hampered by pandemic-driven restrictions. Normalization in marketing activities should drive improved results for Trintellix, Re...

H. Lundbeck A/S (HLUKF) Q4 2021 Earnings Conference Call February 9, 2022 07:00 ET Company Participants Deborah Dunsire - President and Chief Executive Officer Anders Gotzsche - Executive Vice President and Chief Financial Officer Johan Luthman - Executive Vice President, Research and Develop...

Despite supply chain disruptions and labor shortages, the pharma industry is well-positioned to continue growing due to the increasing medical needs of an aging population and advancements in treating chronic diseases. Therefore, amid current market volatility, we believe it could be wise to ...

The following slide deck was published by H. Lundbeck A/S in conjunction with their 2021 Q3 earnings call. For further details see: H. Lundbeck A/S 2021 Q3 - Results - Earnings Call Presentation

H. Lundbeck A/S (HLUKF) Q3 2021 Earnings Conference Call November 10, 2021 07:00 AM ET Company Participants Deborah Dunsire - President & CEO Johan Luthman - EVP of Research & Development Anders Götzsche - Executive VP & CFO Jacob Tolstrup - EVP of Commercial Operations Peter...

The following slide deck was published by H. Lundbeck A/S in conjunction with their 2021 Q2 earnings call. For further details see: H. Lundbeck A/S 2021 Q2 - Results - Earnings Call Presentation

H. Lundbeck A/S (HLUKF) Q2 2021 Earnings Conference Call August 18, 2021 07:00 ET Company Participants Deborah Dunsire - President and Chief Executive Officer Anders Götzsche - Executive Vice President and Chief Financial Officer Johan Luthman - Executive Vice President, Research & D...

With the interim analysis of the Rexulti Alzheimer's agitation study leading to study continuation, Lundbeck's cupboard of near-term catalysts is looking pretty bare. A strong efficacy signal in the Phase II Rexulti study in borderline personality disorder or strong acceleration in Vy...